MCID: INT395
MIFTS: 43

Intracranial Meningioma

Categories: Cancer diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Intracranial Meningioma

MalaCards integrated aliases for Intracranial Meningioma:

Name: Intracranial Meningioma 11 53 14
Meningioma 43

Classifications:



External Ids:

Disease Ontology 11 DOID:0080842
MeSH 43 D008579
NCIt 49 C4656
SNOMED-CT 68 302820008
UMLS 71 C0349604

Summaries for Intracranial Meningioma

Disease Ontology: 11 A meningioma that arises within the cranial cavity.

MalaCards based summary: Intracranial Meningioma, also known as meningioma, is related to tuberculum sellae meningioma and cerebellopontine angle meningioma. An important gene associated with Intracranial Meningioma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Signal Transduction and Validated nuclear estrogen receptor alpha network. The drugs Thrombin and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and pituitary, and related phenotypes are Increased Nanog expression and Increased proliferation

Related Diseases for Intracranial Meningioma

Diseases related to Intracranial Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1317)
# Related Disease Score Top Affiliating Genes
1 tuberculum sellae meningioma 32.4 TRAF7 NF2
2 cerebellopontine angle meningioma 32.2 SMARCE1 NF2
3 pineal region meningioma 32.2 SMARCB1 NF2
4 sphenoorbital meningioma 31.9 TRAF7 SMARCE1 NF2
5 childhood meningioma 31.8 TRAF7 SMARCE1 SMARCB1 NF2
6 foramen magnum meningioma 31.8 TRAF7 POLR2A NF2
7 cavernous sinus meningioma 31.5 TRAF7 SMARCE1 POLR2A NF2
8 rhabdoid meningioma 31.5 TRAF7 SMARCE1 SMARCB1 POLR2A NF2
9 neurofibromatosis, type i 31.5 SST NF2 NF1
10 microcystic meningioma 31.4 TRAF7 SSTR2 SMARCE1 NF2 MIB1
11 psammomatous meningioma 31.4 TRAF7 SSTR2 POLR2A PGR NF2
12 olfactory groove meningioma 31.3 TRAF7 SMARCE1 SMARCB1 POLR2A NF2
13 anterior cranial fossa meningioma 31.2 TRAF7 SMARCE1 SMARCB1 POLR2A NF2
14 clear cell meningioma 31.2 TRAF7 SMARCE1 SMARCB1 POLR2A PGR NF2
15 bap1 tumor predisposition syndrome 31.1 SMARCE1 SMARCB1 NF2 NF1 LZTR1
16 cerebral convexity meningioma 31.1 TRAF7 SMARCE1 SMARCB1 POLR2A NF2
17 spinal meningioma 31.1 TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
18 optic nerve sheath meningioma 31.0 TRAF7 SSTR2 SST SMARCB1 NF2 NF1
19 brain meningioma 30.9 TRAF7 SSTR2 SST SMARCE1 SMARCB1 PGR
20 supratentorial meningioma 30.6 VEGFA NF2
21 lung meningioma 30.5 PGR NF2
22 epidural spinal canal neoplasm 30.5 NF2 NF1
23 neurofibroma 30.4 VEGFA NF2 NF1
24 spinal cord disease 30.4 VEGFA NF2 NF1
25 cerebellopontine angle tumor 30.4 SMARCB1 NF2
26 brain cancer 30.3 VEGFA SMARCB1 NF2 NF1
27 spinal cord ependymoma 30.3 SMARCB1 NF2
28 orbital cancer 30.3 NF2 NF1
29 carcinoid tumors, intestinal 30.3 SSTR2 SST
30 petroclival meningioma 30.2 TRAF7 NF2
31 carcinoid syndrome 30.2 VEGFA SST
32 spinal canal and spinal cord meningioma 30.2 TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
33 multiple endocrine neoplasia, type i 30.1 SSTR2 SST NF1 ARMC5
34 fibroma 30.1 PGR NF1 ESR1
35 neurilemmoma of the fifth cranial nerve 30.1 NF2 NF1
36 prolactinoma 30.1 SSTR2 SST ESR1
37 neuroma 30.0 SMARCB1 PCNA NF2 NF1 LZTR1
38 neuroendocrine carcinoma 30.0 SST PGR ESR1
39 optic nerve glioma 30.0 NF2 NF1 MIB1
40 insulin-like growth factor i 29.9 VEGFA SST ESR1
41 leiomyoma 29.9 PGR PCNA MKI67 ESR1
42 lymphangioleiomyomatosis 29.9 VEGFA PGR ESR1
43 chordoid meningioma 29.9 TRAF7 SMARCB1 PGR NF2
44 cowden syndrome 29.9 PGR NF2 NF1 ESR1
45 atypical teratoid rhabdoid tumor 29.9 SMARCE1 SMARCB1 NF2 NF1
46 benign meningioma 29.9 TRAF7 POLR2A PGR PCNA NF2 MKI67
47 acoustic neuroma 29.8 SMARCB1 NF2 NF1 LZTR1
48 basal cell nevus syndrome 29.8 SMARCB1 NF2 NF1
49 von hippel-lindau syndrome 29.8 VEGFA SST NF1
50 neurofibromatosis 29.8 VEGFA SMARCB1 NF2 NF1 LZTR1

Graphical network of the top 20 diseases related to Intracranial Meningioma:



Diseases related to Intracranial Meningioma

Symptoms & Phenotypes for Intracranial Meningioma

GenomeRNAi Phenotypes related to Intracranial Meningioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 ARMC5 DCAF8 ESR1 LZTR1 MIB1 MKI67
2 no effect GR00402-S-2 10.14 ARMC5 DCAF8 MIB1 MKI67 NDRG2 NF1
3 Increased Nanog expression GR00371-A-1 9.61 MKI67 PCNA SMARCB1 SMARCE1 VEGFA
4 Increased Nanog expression GR00371-A-2 9.61 SMARCE1 VEGFA
5 Increased Nanog expression GR00371-A-4 9.61 VEGFA
6 Increased Nanog expression GR00371-A-5 9.61 VEGFA
7 Increased proliferation GR00094-A 9.16 NF2 SMARCB1

MGI Mouse Phenotypes related to Intracranial Meningioma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 ARMC5 DCAF8 ESR1 MIB1 MKI67 NDRG2
2 growth/size/body region MP:0005378 10.27 ARMC5 DCAF8 ESR1 LZTR1 MIB1 NF1
3 neoplasm MP:0002006 10.19 ESR1 MKI67 NDRG2 NF1 NF2 PGR
4 immune system MP:0005387 10.17 DCAF8 ESR1 MKI67 NDRG2 NF1 NF2
5 normal MP:0002873 10.13 ESR1 MIB1 MKI67 NF1 PGR POLR2A
6 no phenotypic analysis MP:0003012 10.11 ESR1 MIB1 MKI67 PCNA PGR POLR2A
7 embryo MP:0005380 10.1 ARMC5 ESR1 MIB1 NDRG2 NF1 NF2
8 endocrine/exocrine gland MP:0005379 10.09 ARMC5 ESR1 MIB1 NF1 NF2 PCNA
9 liver/biliary system MP:0005370 10.04 DCAF8 ESR1 NF1 NF2 POLR2A SMARCB1
10 digestive/alimentary MP:0005381 10.02 ESR1 MIB1 NF1 NF2 POLR2A SMARCB1
11 hematopoietic system MP:0005397 9.93 DCAF8 ESR1 LZTR1 MIB1 NDRG2 NF1
12 skeleton MP:0005390 9.91 ESR1 LZTR1 MIB1 NDRG2 NF1 NF2
13 mortality/aging MP:0010768 9.83 ARMC5 ESR1 LZTR1 MIB1 NDRG2 NF1
14 integument MP:0010771 9.32 ESR1 MIB1 NDRG2 NF1 NF2 PGR

Drugs & Therapeutics for Intracranial Meningioma

Drugs for Intracranial Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic acid Approved Phase 4 1197-18-8 5526
3
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Prilocaine Approved Phase 4 721-50-6 4906
6 Fibrin Tissue Adhesive Phase 4
7 Anesthetics, Local Phase 4
8 Anesthetics Phase 4
9 Antifibrinolytic Agents Phase 4
10 Hemostatics Phase 4
11 Coagulants Phase 4
12 Vasoconstrictor Agents Phase 4
13 Epinephryl borate Phase 4
14 Bronchodilator Agents Phase 4
15 Neurotransmitter Agents Phase 4
16 Adrenergic beta-Agonists Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic Agents Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Respiratory System Agents Phase 4
22 Mydriatics Phase 4
23 Sympathomimetics Phase 4
24
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
25
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
26
Cisatracurium Approved, Investigational Phase 3 96946-41-7 62887
27
Magnesium sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9
28
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Aminolevulinic acid Approved Phase 3 106-60-5 137
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34 glucocorticoids Phase 3
35 Contraceptives, Postcoital Phase 3
36 Contraceptives, Oral Phase 3
37 Contraceptive Agents Phase 3
38 Progestins Phase 3
39 Antihypertensive Agents Phase 3
40 Photosensitizing Agents Phase 3
41 Dermatologic Agents Phase 3
42
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
43
Aldesleukin Approved Phase 2 110942-02-4
44
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Hydroxyurea Approved Phase 2 127-07-1 3657
47
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
48
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
49
Verapamil Approved Phase 2 152-11-4, 52-53-9 2520
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
13 A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas Recruiting NCT05130866 Phase 2, Phase 3 REC-2282;Placebo
14 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
15 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Unknown status NCT03016091 Phase 2 Pembrolizumab
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
18 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
19 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
20 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
21 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
22 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
23 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
24 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
25 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
26 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
27 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
28 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
29 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
30 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
31 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
32 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
33 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
34 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
35 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
36 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
37 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
38 Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations Recruiting NCT02523014 Phase 2 Vismodegib;FAK Inhibitor GSK2256098;Capivasertib;Abemaciclib
39 A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma Recruiting NCT02847559 Phase 2
40 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
41 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
42 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
43 SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Recruiting NCT04298541 Phase 2 Ga-68- DOTATATE;Ga-68-DOTATOC
44 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
45 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
46 An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma Recruiting NCT05023018 Phase 2 NEO100
47 A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma Recruiting NCT05425004 Phase 2 Cabozantinib
48 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
49 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
50 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab

Search NIH Clinical Center for Intracranial Meningioma

Cochrane evidence based reviews: meningioma

Genetic Tests for Intracranial Meningioma

Anatomical Context for Intracranial Meningioma

Organs/tissues related to Intracranial Meningioma:

MalaCards : Brain, Spinal Cord, Pituitary, Breast, Lung, Bone, Endothelial

Publications for Intracranial Meningioma

Articles related to Intracranial Meningioma:

(show top 50) (show all 932)
# Title Authors PMID Year
1
Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs. 53 62
19175733 2009
2
Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. 53 62
8613841 1996
3
Growth rate of intracranial meningioma: tumor doubling time and proliferating cell nuclear antigen staining index. 53 62
7623949 1995
4
Multiple recurrences of unknown primary tumor in a meningioma: A case report. 62
35488191 2022
5
Health-related quality of life and clinical outcome after radiotherapy of patients with intracranial meningioma. 62
36396802 2022
6
Evaluating diploic vein blood flow using time-resolved whole-head computed tomography angiography and determining the positional relationship between typical craniotomy approaches and diploic veins in patients with meningioma. 62
36006508 2022
7
Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study. 62
36378400 2022
8
Radiological Differentiation Between Intracranial Meningioma and Solitary Fibrous Tumor/Hemangiopericytoma: A Systematic Literature Review. 62
36403933 2022
9
Brain infarction following meningioma surgery-incidence, risk factors, and impact on function, seizure risk, and patient-reported quality of life. 62
35902426 2022
10
Tumor-to-tumor metastasis-Metastasis of pulmonary adenocarcinoma to intracranial meningioma: A case report. 62
36308218 2022
11
The use of an endoscopic endonasal approach for a secondary intraorbital meningioma: illustrative case. 62
36083773 2022
12
Impact of COVID-19 on Intracranial Meningioma Resection: Results from California State Inpatient Database. 62
36230707 2022
13
Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. 62
35621369 2022
14
Hypofractionated Radiosurgery for Large or in Critical-Site Intracranial Meningioma: Results of a Phase 2 Prospective Study. 62
36075299 2022
15
Perioperative Clinical Course Variables Associated with Length of Hospital Stay after Primary Intracranial Meningioma Resection. 62
36123152 2022
16
Impact of a cell cycle and an extracellular matrix remodeling transcriptional signature on tumor progression and correlation with EZH2 expression in meningioma. 62
36029259 2022
17
Single session versus multisession stereotactic radiosurgery for the management of intracranial meningiomas: a systematic review and meta-analysis. 62
35976546 2022
18
Combined Exoscopic and Endoscopic Two-Step Keyhole Approach for Intracranial Meningiomas. 62
36005164 2022
19
Editorial for "Fully Automated MRI Segmentation and Volumetric Measurement of Intracranial Meningioma Using Deep Learning". 62
35778673 2022
20
Fully Automated MRI Segmentation and Volumetric Measurement of Intracranial Meningioma Using Deep Learning. 62
35775971 2022
21
Cerebral meningioma associated with extensive calvarium osteolysis and presumed intratumoral carcinoma metastasis in a cat. 62
36132420 2022
22
The Long and Winding Road: An Overview of the Immunological Landscape of Intracranial Meningiomas. 62
35892898 2022
23
Association of baseline frailty status and age with outcomes in patients undergoing intracranial meningioma surgery: Results of a nationwide analysis of 5818 patients from the National Surgical Quality Improvement Program (NSQIP) 2015-2019. 62
35216859 2022
24
A rare case of metastatic atypical meningioma that highlights the shortcomings of treatment options at present. 62
35833195 2022
25
The Surgical Risk Factors of Giant Intracranial Meningiomas: A Multi-Centric Retrospective Analysis of Large Case Serie. 62
35884624 2022
26
Supervised machine learning algorithms demonstrate proliferation index correlates with long-term recurrence after complete resection of WHO grade I meningioma. 62
36303473 2022
27
Canine intracranial meningioma with rosette-like collagen deposits. 62
35491093 2022
28
Letter: Association of Late Week Nonhome Discharge With Increased Length of Stay in Intracranial Meningioma Resection Patients. 62
35442224 2022
29
Anxiety and depression in patients with intracranial meningioma: a mixed methods analysis. 62
35395829 2022
30
Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series. 62
34850321 2022
31
Characterization of volumetric growth of intracranial meningiomas in Māori and Pasifika populations in New Zealand. 62
35239240 2022
32
A Spotlight on the Role of Radiomics and Machine-Learning Applications in the Management of Intracranial Meningiomas: A New Perspective in Neuro-Oncology: A Review. 62
35455077 2022
33
Presentation and management of spinal meningioma and its association with breast carcinoma-case series and systematic review. 62
35435093 2022
34
Are there predilection sites for intracranial meningioma? A population-based atlas. 62
34674099 2022
35
The effect of socioeconomic status on age at diagnosis and overall survival in patients with intracranial meningioma. 62
32878534 2022
36
Clinical presentation, diagnostic findings and outcome of dogs undergoing surgical resection for intracranial meningioma: 101 dogs. 62
35249530 2022
37
Atypical Presentation of Transcranial Extension of Intracranial Meningiomas. 62
35171886 2022
38
Evaluation of Surgical Cleavage Plane by Preoperative Magnetic Resonance Imaging Findings in Adult Intracranial Meningiomas. 62
35454964 2022
39
Bibliometric analysis of the top 100 cited articles on stereotactic radiosurgery of intracranial meningiomas. 62
35142245 2022
40
Sinonasal mycosis following transfrontal craniotomy in three dogs. 62
34986118 2022
41
Clinicopathologic Characteristics of Grade 2/3 Meningiomas: A Perspective on the Role of Next-Generation Sequencing. 62
35774130 2022
42
Application of MRI-Based Radiomics in Preoperative Prediction of NF2 Alteration in Intracranial Meningiomas. 62
36267986 2022
43
Intraoperative Real-Time Near-Infrared Image-Guided Surgery to Identify Intracranial Meningiomas via Microscope. 62
35600609 2022
44
Critical appraisal of minimally invasive keyhole surgery for intracranial meningioma in a large case series. 62
35901061 2022
45
Preoperative Prediction of Intracranial Meningioma Grade Using Conventional CT and MRI. 62
35228967 2022
46
External validation and recalibration of an incidental meningioma prognostic model - IMPACT: protocol for an international multicentre retrospective cohort study. 62
35042706 2022
47
Intracranial meningioma surveillance using volumetrics from T2-weighted MRI. 62
34506680 2022
48
Epidemiology and Survival after Spinal Meningioma Surgery: A Nationwide Population-Based Study. 62
35051328 2022
49
Intracranial Meningioma in Elderly Patients. Retrospective Multicentric Risk and Surgical Factors Study of Morbidity and Mortality. 62
35204442 2022
50
Distress and quality of life do not change over time in patients with operated and conservatively managed intracranial meningioma. 62
34643803 2021

Variations for Intracranial Meningioma

Expression for Intracranial Meningioma

Search GEO for disease gene expression data for Intracranial Meningioma.

Pathways for Intracranial Meningioma

Pathways related to Intracranial Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 13.02 VEGFA SSTR2 SST POLR2A PGR NF2
2 11.14 PGR PCNA ESR1
3
Show member pathways
10.77 VEGFA SMARCE1 SMARCB1 ESR1
4 10.65 PGR ESR1
5 10.5 SMARCE1 SMARCB1
6 10.37 PGR ESR1

GO Terms for Intracranial Meningioma

Cellular components related to Intracranial Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bBAF complex GO:0140092 8.92 SMARCE1 SMARCB1

Biological processes related to Intracranial Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell differentiation GO:0045597 9.73 SMARCE1 SMARCB1 NF2
2 intracellular steroid hormone receptor signaling pathway GO:0030518 9.62 PGR ESR1
3 negative regulation of Schwann cell proliferation GO:0010626 9.46 NF2 NF1
4 vascular associated smooth muscle cell proliferation GO:1990874 9.26 NF1 NDRG2
5 Schwann cell proliferation GO:0014010 8.92 NF2 NF1

Sources for Intracranial Meningioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....